Amongst the controversy regarding the effectiveness of drugs meant to treat individuals with Alzheimer's, Pfizer recently announced that the FDA has approved a new once daily 23 mg tablet of Aricept, for the treatment of moderate to severe Alzheimer's disease. The approval of this new dose is based on data from a large study of 1,467 participants who received either a 10 mg dose or a 23 mg dose of the drug. In comparing global function via the Clinician's Interview-Based Impression of Change Plus Caregiver Input Scale (CIBIC plus) and cognition via the Severe Impairment Battery (SIB), it was found that while the scores on global functioning were not statistically different between the two doses, that improvements in cognition were statistically higher for individuals receiving the 23 mg dose. It is worth noting that both the CIBIC plus and the SIB have been validated in those with Alzheimer's and other dementias. It is therefore hoped that this higher dose may provide additional symptomatic relief for some patients. The availability of this dose is expected to reach pharmacies in the next couple of weeks.
The press release regarding this new dose can be accessed here.